XOMA (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average - Here's Why

Shares of XOMA Co. (NASDAQ:XOMA - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $26.54 and traded as high as $30.98. XOMA shares last traded at $30.86, with a volume of 13,013 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on XOMA shares. HC Wainwright reissued a "buy" rating and set a $117.00 target price on shares of XOMA in a research note on Wednesday, October 23rd. StockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research note on Wednesday, August 14th.

XOMA Stock Up 0.5 %

The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71. The business has a fifty day simple moving average of $28.34 and a 200 day simple moving average of $26.58. The firm has a market cap of $362.93 million, a price-to-earnings ratio of -12.39 and a beta of 0.90.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The firm had revenue of $11.09 million during the quarter, compared to analysts' expectations of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. As a group, equities analysts forecast that XOMA Co. will post -1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its stake in XOMA by 55.6% during the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 1,266 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after purchasing an additional 1,334 shares during the period. Bank of New York Mellon Corp grew its position in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock valued at $1,484,000 after buying an additional 1,968 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in XOMA in the 1st quarter valued at $212,000. Finally, Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the 3rd quarter worth $516,000. 95.92% of the stock is owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.